Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibiting the MNK-eIF4E-β-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy.

Oncotarget - 10 Jan 2017

Li Zhiqiang, Sun Yang, Qu Miao, Wan Hongxing, Cai Fang, Zhang Peng

Abstract excerpt

Advanced breast cancer (eg. stage IV) is resistant to chemotherapy. In this work, we identified potentially druggable targets that are critically involved in chemoresistance. We showed that eIF4E is highly phosphorylated at serine 209 in breast cancer patients in response to chemotherapy, which significantly correlated with poorer clinical responses and outcomes. Depletion of eIF4E enhanced the anti-proliferative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Apoptosis

Share to beta Catenin

Share to Copper-Transporting ATPases

Share to Drug Resistance, Neoplasm

Share to Eukaryotic Initiation Factor-4E

Share to Kaplan-Meier Estimate

Source

Open in PubMed Open full text

Identifiers

PMID: 27926520
DOI: 10.18632/oncotarget.13772
PMCID: PMC5356851

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibiting the MNK-eIF4E-β-catenin axis increases the responsiveness of aggressive breast cancer cells to chemotherapy.PMID 27926520Read ↗

Targeting Mnks for Cancer TherapySemantic proximity Read ↗

The role of MNK proteins and eIF4E phosphorylation in breast cancer cell proliferation and survivalSemantic proximity Read ↗

Targeting EIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancerSemantic proximity Read ↗

Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.Semantic proximity Read ↗

Targeting the Eukaryotic Translation Initiation Factor 4E for Cancer TherapySemantic proximity Read ↗

FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cellsSemantic proximity Read ↗

MLK4 regulates DNA damage response and promotes triple-negative breast cancer chemoresistanceSemantic proximity Read ↗

The pleiotropic effects of the MNK1/2-eIF4E axis support immune suppression and metastasis in a model of postpartum breast cancerSemantic proximity Read ↗

Phosphorylated eukaryotic translation initiation factor 4 (eIF4E) is elevated in human cancer tissuesSemantic proximity Read ↗

Robust eIF4B levels undermine invasive growth and immune evasion mechanisms in murine triple negative breast cancer modelsSemantic proximity Read ↗

MiR ‐379‐5p inhibits the proliferation, migration, and invasion of breast cancer by targeting KIF4ASemantic proximity Read ↗

Marizomib suppresses triple-negative breast cancer via proteasome and oxidative phosphorylation inhibitionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.